- Home
- ACB vs AARD Comparison
ACB vs AARD Comparison
Compare ACB & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | AARD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 40 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.3M | 85.7M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACB | AARD |
|---|---|---|
| Price | $3.68 | $5.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | ★ 587.5K | 235.6K |
| Earning Date | 02-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $3.35 |
| 52 Week High | $6.67 | $17.94 |
Technical Indicators
Market Signals| Indicator | ACB | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 49.59 |
| Support Level | $3.28 | $4.74 |
| Resistance Level | $3.91 | $6.19 |
| Average True Range (ATR) | 0.14 | 0.32 |
| MACD | 0.05 | 0.37 |
| Stochastic Oscillator | 97.71 | 97.47 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.